NCT07006168 Effects Of Intra-Operative Intra-Articular Cocktail Injection In Patella Open Reduction And Internal Fixation
| NCT ID | NCT07006168 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | The University of Hong Kong |
| Condition | Patella Fracture |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 56 participants in total. It began in 2024-11-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to demonstrate the safety and efficacy of an intra-articular analgesics cocktail injection for post-operative patella fracture fixation patients, by comparing post-operative pain relief and functional recovery among study subjects who received the injection and those who did not receive the injection. Secondary objective is to demonstrate the health economic effects of intra-articular analgesics cocktail injection by reducing length of hospital stay and reducing bed-stay related complications.
Eligibility Criteria
Inclusion Criteria: * acute patella fracture requiring open reduction and internal fixation; * able to consent to surgery; * pre-morbid able to ambulate Exclusion Criteria: * open fracture; * polytrauma; * previous knee arthroplasty; * history of chronic pain, * insulin-dependent diabetes mellitus, or peptic ulcer disease; * chronic users of glucocorticoids, immunosuppressants, or immune-modulating agents, or of strong opioids (e.g.: morphine, fentanyl, hydromorphone, methadone, oxycodone, or meperidine); * hepatitis B or C carrier; * renal impairment (creatinine \[Cr\], \>200 mmol/L)
Contact & Investigator
Christian Fang
PRINCIPAL INVESTIGATOR
Dept of Orthopaedics and Traumatology, Queen Mary Hospital
Frequently Asked Questions
Who can join the NCT07006168 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Patella Fracture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07006168 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07006168 currently recruiting?
Yes, NCT07006168 is actively recruiting participants. Contact the research team at cfang@hku.hk for enrollment information.
Where is the NCT07006168 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT07006168 clinical trial?
NCT07006168 is sponsored by The University of Hong Kong. The principal investigator is Christian Fang at Dept of Orthopaedics and Traumatology, Queen Mary Hospital. The trial plans to enroll 56 participants.